Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Unternehmen & Branche
| Name | Janux Therapeutics, Inc. |
|---|---|
| Ticker | JANX |
| CIK | 0001817713 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 854,1 Mio. USD |
| Beta | 2,81 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -113,625,000 | -1.83 | 1,001,565,000 | 956,822,000 | |
| 2025-09-30 | 10-Q | -24,313,000 | -0.39 | 1,024,766,000 | 976,555,000 | |
| 2025-06-30 | 10-Q | -33,858,000 | -0.55 | 1,032,212,000 | 990,516,000 | |
| 2025-03-31 | 10-Q | -23,508,000 | -0.38 | 1,050,772,000 | 1,012,469,000 | |
| 2024-12-31 | 10-K | -68,994,000 | -1.28 | 1,061,516,000 | 1,022,781,000 | |
| 2024-09-30 | 10-Q | -28,059,000 | -0.51 | 695,019,000 | 656,104,000 | |
| 2024-06-30 | 10-Q | -5,959,000 | -0.11 | 691,412,000 | 657,677,000 | |
| 2024-03-31 | 10-Q | -14,760,000 | -0.30 | 688,984,000 | 655,763,000 | |
| 2023-12-31 | 10-K | -58,293,000 | -1.32 | 380,407,000 | 344,349,000 | |
| 2023-09-30 | 10-Q | -11,568,000 | -0.25 | 386,850,000 | 348,948,000 | |
| 2023-06-30 | 10-Q | -17,508,000 | -0.42 | 341,500,000 | 299,469,000 | |
| 2023-03-31 | 10-Q | -17,459,000 | -0.42 | 352,956,000 | 311,264,000 | |
| 2022-12-31 | 10-K | -63,059,000 | -1.52 | 364,010,000 | 320,740,000 | |
| 2022-09-30 | 10-Q | -16,696,000 | -0.40 | 375,756,000 | 331,513,000 | |
| 2022-06-30 | 10-Q | -16,888,000 | -0.41 | 385,365,000 | 343,814,000 | |
| 2022-03-31 | 10-Q | -13,410,000 | -0.32 | 368,597,000 | 356,082,000 | |
| 2021-12-31 | 10-K | -32,672,000 | -1.39 | 379,824,000 | 366,327,000 | |
| 2021-09-30 | 10-Q | -10,766,000 | -0.26 | 391,084,000 | 376,750,000 | |
| 2021-06-30 | 10-Q | -6,206,000 | -0.62 | 396,823,000 | 384,795,000 | |
| 2021-03-31 | 10-Q | -2,284,000 | -16,771,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-01-02 | Dobek Maria | Officer, Vice President, Accounting | Open Market Sale | -1,462 | 13.73 | -20,073.26 | -20,6% | |
| 2026-01-02 | DiRaimondo Thomas | Officer, Chief Scientific Officer | Open Market Sale | -2,505 | 13.73 | -34,393.65 | -35,4% | |
| 2026-01-02 | Campbell David Alan | Director, Officer, President and CEO | Open Market Sale | -8,072 | 13.73 | -110,828.56 | -114,0% | |
| 2026-01-02 | Winter Charles M. | Officer, Chief Technical Officer | Open Market Sale | -2,401 | 13.73 | -32,965.73 | -33,9% | |
| 2026-01-02 | McIver Zachariah | Officer, Chief Medical Officer | Open Market Sale | -2,714 | 13.73 | -37,263.22 | -38,3% | |
| 2026-01-02 | Meyer Andrew Hollman | Officer, Chief Business Officer | Open Market Sale | -1,879 | 13.73 | -25,798.67 | -26,5% | |
| 2025-12-01 | Meyer Andrew Hollman | Officer, Chief Business Officer | Open Market Sale | -633 | 33.52 | -21,221.14 | -21,8% | |
| 2025-12-01 | Meyer Andrew Hollman | Officer, Chief Business Officer | Open Market Sale | -2,700 | 32.85 | -88,707.96 | -91,2% | |
| 2025-11-14 | Meyer Andrew Hollman | Officer, Chief Business Officer | Open Market Sale | -3,333 | 30.00 | -99,990.00 | -102,8% | |
| 2025-10-28 | Meyer Andrew Hollman | Officer, Chief Business Officer | Open Market Sale | -16,665 | 30.06 | -500,986.56 | -515,3% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.